News | Patient Positioning Radiation Therapy | September 08, 2017

U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatment

Decision based on data involving use of SpaceOAR hydrogel to protect surrounding tissue during radiotherapy to treat prostate cancer

U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatement

September 8, 2017 — Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the U.K. has issued Interventional Procedure Guidance (IPG) supporting the use of a hydrogel barrier to reduce the risk of toxicity to surrounding tissue in radiotherapy to treat prostate cancer. The guidance recommends use of hydrogel spacers under "standard arrangements". For a procedure to be recommended for use with standard arrangements (previously called “normal arrangements”), the evidence should be adequate to show safety and efficacy of the procedure both in the long term and short term. NICE’s guidance clearly indicates that this procedure meets the highest evidence standards.

The designation is based in part on three-year follow-up data from a Phase III prospective, randomized clinical trial involving the use of SpaceOAR hydrogel, a technology developed by Augmenix to reduce the risk of rectal injury in men receiving prostate cancer radiation therapy (RT) by acting as a spacer that pushes the rectum away from the prostate during treatment.

The IPG designation positions U.K. radiation oncologists and urologists to offer use of a hydrogel spacer such as SpaceOAR as an option for men with prostate cancer who want to reduce their risk of side effects including rectal toxicity, incontinence and loss of sexual function associated with radiotherapy.

“Radiation therapy has been proven to be a highly effective treatment option for many men with prostate cancer, but in many cases patients are concerned about potential side effects related to rectal toxicity, incontinence or sexual function,” said Prof. Heather Payne, a consultant in clinical oncology at University College Hospital, London. “The IPG designation provides important further validation of the benefits of a hydrogel barrier in reducing the risk of side effects, helping patients to proceed to treatment with greater comfort and confidence.”

SpaceOAR hydrogel reduces rectal injury in men receiving prostate cancer radiation therapy by acting as a spacer – pushing the rectum away from the prostate. This space between organs decreases the radiation dose to the rectum and other organs at risk (OAR). Earlier this year, Augmenix announced published data from their prospective, randomized clinical trial showing that patients treated with SpaceOAR hydrogel prior to prostate cancer radiotherapy demonstrated significant rectal (bowel), urinary and sexual benefits through three years of follow-up.

“Our goal in the management of prostate cancer is to identify the most effective treatment options for each patient, and we always have to keep in mind their concerns about side effects that can affect their health and quality of life,” said Suneil Jain, NMD, senior lecturer and consultant in clinical oncology at Queen’s University Belfast. “With SpaceOAR Hydrogel, we have a proven safe option to help address some of the most important concerns that patients have about radiotherapy, including bowel toxicity and loss of sexual function.”

For more information: www.augmenix.com

Related Content

Long-Term Survival Rates More Than Double Previous Estimates for Locally Advanced Lung Cancer
News | Radiation Therapy | September 25, 2017
Long-term results of a phase III clinical trial indicate survival rates for patients receiving chemoradiation for...
IBA Releases Razor Nano Ionization Chamber
News | Proton Therapy | September 22, 2017
September 22, 2017 — IBA (Ion Beam Applications S.A.) announced the release of the Razor Nano Chamber, the smallest a
Penn Medicine Treats World's First Patient on Varian's Halcyon System
News | Radiation Therapy | September 22, 2017
September 22, 2017 — Varian Medical Systems announced a patient at Penn Medicine, with head & neck cancer, became
BrainLAB Announces FDA Clearance For Two New Indication-Specific Radiosurgery Software Applications
Technology | Treatment Planning | September 21, 2017
Brainlab announced that it has received U.S. Food and Drug Administration (FDA) clearance for Elements Spine SRS and...
Accuray Showcases CyberKnife and Radixact Systems at ASTRO 2017
News | Radiation Therapy | September 21, 2017
Accuray Inc. announced that data and first-hand experience with its advanced CyberKnife and Radixact Systems will be...
RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Overlay Init